InnSight Technology wins $515k from Mellon Foundation for OcuCheck
InnSight Technology has received a $515,000 Social Impact Investment from the Richard King Mellon Foundation after winning the Foundation's SII Pitch Competition, the Pittsburgh-based medical device company announced on 30 July 2026. The funding will support engineering, manufacturing, and clinical validation of its OcuCheck tear-fluid diagnostic platform as the company moves toward commercial launch.
OcuCheck is designed to measure multiple biomarkers from a small tear sample within minutes during a routine eye examination, without the need for a blood draw or referral to a specialist facility. The company describes it as the first multiplex electrochemical tear fluid sensor capable of quantitative, simultaneous measurement of MMP-9 and tear fluid osmolarity in a single non-invasive test. InnSight's immediate commercial focus is the diagnosis of dry eye disease, but the broader clinical thesis centres on diabetes screening: with more than 35 million diabetic eye exams conducted annually in the United States, the company argues that eye care providers are well placed to identify at-risk patients before systemic disease progresses.
Technology and unmet need
Diabetes is the leading cause of vision loss among working-age adults in the US, and early detection remains a persistent clinical challenge. Many patients, particularly those in rural or underserved communities, have limited access to primary care but attend regular eye examinations, making the ophthalmic setting a practical intercept point. Leanne Labriola, chief executive of InnSight Technology, said the investment "underscores not only the innovation behind our technology, but its potential to improve lives," and described a long-term vision in which routine eye exams play a wider role in identifying and predicting systemic diseases.
The OcuCheck has not yet received FDA clearance for commercial sale, and the release does not specify a target submission timeline or detail the clinical validation study design that the new funds will support. Those disclosures will be closely watched by both investors and potential commercial partners in the ophthalmology and primary-care diagnostics space.
Market context and competitive landscape
Point-of-care tear fluid diagnostics is a relatively nascent but growing category within in-vitro diagnostics, distinct from the established lateral-flow dry eye tests already on the market. The proposition of using tear biomarkers as a window into systemic disease has attracted academic and commercial interest, with several university-affiliated groups and early-stage companies exploring the space. InnSight's electrochemical multiplexing approach differentiates it from single-analyte immunoassay strips, though peer-reviewed clinical performance data in diabetes populations have not yet been published.
The Richard King Mellon Foundation's Social Impact Investment programme operates through for-profit equity or debt positions aligned with the Foundation's philanthropic goals. The Foundation has deployed more than $32 million across 78 companies via this vehicle, and the competition format adds a credibility signal that may assist InnSight in attracting follow-on private capital. However, at $515,000, the cheque size is modest relative to the cost of a regulatory-grade clinical validation study, suggesting additional fundraising will be needed before an FDA submission is viable.
Pittsburgh has invested substantially in its life sciences ecosystem over the past decade, and InnSight joins a cluster of diagnostics and digital health companies that have benefited from that regional infrastructure. The next material milestones to watch will be publication of clinical data, a named indication for the first regulatory submission, and any announcement of Series A activity.